Glaukos Corporation (GKOS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 225 | 294 | 283 | 315 | 383 | 507 | 613 | 691 |
| Operating profit | $m | -87 | -80 | ||||||
| Net profit | $m | -120 | -50 | -99 | -135 | -146 | -188 | -188 | -17 |
| EPS reported | $ | -3.28 | -3.25 | ||||||
| Operating cashflow per share | $ | -0.81 | -0.02 | ||||||
| Capex per share | $ | 0.13 | 0.19 | ||||||
| FCF per share | $ | -0.94 | -0.21 | ||||||
| Free cash flow | $m | -54 | -12 | ||||||
| Net debt | $m | -243 | -286 | ||||||
| Book value equity | $m | 656 | 682 | ||||||
| Book value per share | $ | 11.47 | 11.68 | ||||||
| Number of shares | m | 57.19 | 58.42 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 9.84 | 9.46 | ||||||
| P/S LTM | x | 12.73 | 10.54 | ||||||
| P/FCF LTM | x | -119.57 | -529.46 | ||||||
| EV/EBITDA LTM | x | -44.54 | -45.73 | ||||||
| EV/Sales LTM | x | 12.82 | 17.74 | ||||||
| Earnings Yield LTM | % | -2.91% | -1.74% | ||||||
| FCF Yield | % | -0.84% | -0.19% | ||||||
| Quality | |||||||||
| ROE | % | -28.60% | -27.07% | ||||||
| ROIC | % | -10.64% | -9.59% | ||||||
| Operating margin | % | -17.09% | -13.13% | ||||||
| Gross margin | % | +77.49% | +79.12% | ||||||
| FCF/Sales | % | -10.64% | -1.99% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +32.33% | +59.81% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.39 | -0.12 | ||||||
| Net Debt/EBITDA | x | -0.33 | 0.08 | ||||||
| EBIT/Net interest | x | -18.71 | -16.41 | ||||||
| Net debt/market cap | % | +0.55% | +0.94% | ||||||
| Net debt/Equity | x | -0.37 | -0.42 | ||||||
| Gross debt/equity | x | 0.21 | 0.15 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free